298 related articles for article (PubMed ID: 25212889)
41. [Role of bortezomib in the treatment of multiple myeloma].
Gotoh A; Ohyashiki K
Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
[TBL] [Abstract][Full Text] [Related]
42. Management of myeloma: an Italian perspective.
Bruno B; Gay F; Boccadoro M; Palumbo A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
[TBL] [Abstract][Full Text] [Related]
43. Novel therapeutic targets in multiple myeloma.
Cottini F; Anderson K
Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
[TBL] [Abstract][Full Text] [Related]
44. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
45. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
46. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
47. Emerging role of novel combinations for induction therapy in multiple myeloma.
Voorhees PM; Orlowski RZ
Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
[TBL] [Abstract][Full Text] [Related]
48. Future novel single agent and combination therapies.
Cirstea D; Vallet S; Raje N
Cancer J; 2009; 15(6):511-8. PubMed ID: 20010171
[TBL] [Abstract][Full Text] [Related]
49. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
50. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
51. Novel therapeutic targets for multiple myeloma.
Mahindra A; Cirstea D; Raje N
Future Oncol; 2010 Mar; 6(3):407-18. PubMed ID: 20222797
[TBL] [Abstract][Full Text] [Related]
52. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
53. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
54. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
55. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
56. Daratumumab granted breakthrough drug status.
Laubach JP; Tai YT; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
[TBL] [Abstract][Full Text] [Related]
57. Novel lenalidomide-based combinations for treatment of multiple myeloma.
Cives M; Simone V; Brunetti O; Longo V; Silvestris F
Crit Rev Oncol Hematol; 2013 Jan; 85(1):9-20. PubMed ID: 22809697
[TBL] [Abstract][Full Text] [Related]
58. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
59. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
60. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]